[EN] POLYCYCLIC PYRROLIDINE-2,5-DIONE DERIVATIVES AS -FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS [FR] DÉRIVÉS POLYCYCLIQUES DE PYRROLIDINE-2,5-DIONE EN TANT QUE MODULATEURS DU RÉCEPTEUR FPRL-1 (RÉCEPTEUR DE N-FORMYL PEPTIDE DE TYPE 1)
[EN] POLYCYCLIC PYRROLIDINE-2,5-DIONE DERIVATIVES AS -FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS [FR] DÉRIVÉS POLYCYCLIQUES DE PYRROLIDINE-2,5-DIONE EN TANT QUE MODULATEURS DU RÉCEPTEUR FPRL-1 (RÉCEPTEUR DE N-FORMYL PEPTIDE DE TYPE 1)
DERIVATIVES OF CYCLOALKYL- AND CYCLOALKENYL-1,2-DICARBOXYLIC ACID COMPOUNDS HAVING FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) AGONIST OR ANTAGONIST ACTIVITY
申请人:Beard Richard L.
公开号:US20110319454A1
公开(公告)日:2011-12-29
The invention provides well defined compounds having FPRL-1 agonist or antagonist activity. As such, the compounds of the invention are useful for treating a variety of ocular disorders.
Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity
申请人:Beard Richard L.
公开号:US08618163B2
公开(公告)日:2013-12-31
The invention provides well defined compounds having FPRL-1 agonist or antagonist activity. As such, the compounds of the invention are useful for treating a variety of ocular disorders.
The present invention relates to novel polycyclic pyrrolidine-2,5-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
US8440684B2
申请人:——
公开号:US8440684B2
公开(公告)日:2013-05-14
[EN] DERIVATIVES OF CYCLOALKYL- AND CYCLOALKENYL-1,2-DICARBOXYLIC ACID COMPOUNDS HAVING FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) AGONIST OR ANTAGONIST ACTIVITY<br/>[FR] DÉRIVÉS D'ACIDES CYCLOALKYL- ET CYCLOALCÉNYL-1,2-DICARBOXYLIQUES PRÉSENTANT UNE ACTIVITÉ AGONISTE OU ANTAGONISTE DU RÉCEPTEUR FPRL-1
申请人:ALLERGAN INC
公开号:WO2011163502A1
公开(公告)日:2011-12-29
The invention provides well defined compounds having FPRL-1 agonist or antagonist activity. As such, the compounds of the invention are useful for treating a variety of ocular disorders.